Skip to content
Screener

Insulet PODD Operating Income

Operating Income at other companies

Tandem Diabetes Care logo
Tandem Diabetes CareTNDM
-$13.79M+73.4%
Medtronic logo
MedtronicMDT
$1.87B+30.4%
Beta Bionics logo
Beta BionicsBBNX
-$25.58M-28.7%
Embecta Corp. logo
Embecta Corp.EMBC
$35M-44.4%
Opko Health logo
Opko HealthOPK
-$6.97M+88.4%
VAN
Vivani MedicalVANI
-$6.82M-4.0%

Other financials

Income statement

See full
Revenue$801.7M+23.5%
Gross profit$562.6M+24.4%
Net income$95.0M+322%
EPS (diluted)$1.37+328%

Balance sheet

See full
Cash & equivalents$534.9M-52.3%
Total debt$974.7M-47.6%
Total equity$1.4B-2.8%
Total assets$3.2B-8.8%

Cash flow

See full
Operating cash flow$88.4M-55.0%
CapEx$32.5M+74.7%
Free cash flow$55.9M-68.6%

Valuation

See full
Market cap$9.23B-52.7%
Enterprise value$9.67B-52.3%
P/E24.6×-58.1×
P/S-5.2×

Profitability

See full
Gross margin71.1%+0.3pp
Operating margin16.9%-0.4pp
Net margin12.3%+2.3pp
FCF margin9.6%-7.5pp

Returns & leverage

See full
Return on equity26%+6.8pp
Debt / equity0.7×-0.6×
Current ratio2.5×+0.2×

Where this comes from

Reported directly by Insulet in its filing.

Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.

The source filing: Insulet’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:06 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001145197-26-000169
(in millions, except share and per share data)Three Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Gross profit562.6452.21,091.6861.3
Research and development expenses88.173.4177.8133.0
Selling, general and administrative expenses344.8257.7662.1518.4
Operating income129.7121.1251.8209.9
Interest expense(13.5)(19.6)(28.2)(28.8)
Interest income3.610.18.520.3
Loss on extinguishment of debt(84.4)(123.9)
Other (expense) income, net(1.1)1.3(0.4)(0.9)

Item 1. Condensed Consolidated Financial Statements (Unaudited)

FAQ

What is Insulet's operating income?
Insulet (PODD) reported operating income of $129.7M in Q2 2026.
How has Insulet's operating income changed year-over-year?
Insulet's operating income increased by 7.1% year-over-year, from $121.1M to $129.7M.
What is the long-term trend for Insulet's operating income?
Over 4 years (2021 to 2025), Insulet's operating income has grown at a 39.3% compound annual growth rate (CAGR), from $126M to $473.9M.
What does operating income mean?
Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.

Ask your AI about Insulet's operating income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude